Denosumab 60 mg/mL, 120 mg/1.7 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 60 mg/mL, 120 mg/1.7 mL

Reference Brands: Prolia, Xgeva

Category: Osteoporosis

Denosumab is available as 60 mg (Prolia) and 120 mg (Xgeva) prefilled syringes for osteoporosis and cancer-related bone conditions. Ideal for global pharma B2B sourcing.

Product Description: Denosumab is a leading RANKL-inhibiting monoclonal antibody used in the treatment of osteoporosis, cancer-related bone loss, and bone metastases. Available as a 60 mg/mL prefilled syringe (Prolia®) for biannual dosing and 120 mg/1.7 mL (Xgeva®) for monthly administration, Denosumab offers effective and long-acting bone protection. Trusted globally under Amgen's Prolia and Xgeva brands, it is approved across the US and EU. Denosumab is manufactured in GMP-certified facilities and is available for B2B pharmaceutical distribution, including hospitals and oncology clinics. Contact us for bulk export, COAs, and regulatory documentation.